THE ROCKEFELLER UNIVERSITY NOT FOR PROFIT CORPORATION

Their core work

The Rockefeller University is a premier US biomedical research institution specializing in fundamental biology and infectious disease. Within H2020, they contributed expertise in immunology, host-pathogen interactions, and human genetics of infection — spanning HIV functional cure research, Alzheimer's neurodegeneration, and childhood bacterial infections. Their role has been that of a specialist knowledge provider brought in by European consortia for their deep bench science in molecular biology and immune mechanisms.

What they specialise in

How they've shifted over time

Early H2020 involvement (2015-2017) centered on fundamental molecular biology — protein modifications (palmitoylation, glycosylation) and their roles in cell function and immunity. From 2017 onward, the focus shifted toward translational infectious disease work, notably HIV immunotherapy and human genetic susceptibility to bacterial infections. This trajectory suggests a move from basic biochemistry toward clinically relevant infection biology and personalised medicine.

Moving toward translational infection research and personalised immune interventions, making them a strong partner for future projects combining genomics with therapeutic development.

How they like to work

Rockefeller University exclusively participates as a third-party or minor partner — never as coordinator — which is typical for a US institution in Horizon 2020 where non-EU entities cannot lead projects. They have connected with 21 partners across 10 countries, indicating they are selectively brought into diverse European consortia for their specialized scientific expertise. This is a "call them when you need world-class bench science" relationship rather than a project management partnership.

Connected to 21 unique partners across 10 countries, reflecting broad but selective engagement with European research groups. Their network spans multiple consortia rather than repeated partnerships, suggesting they are recruited for specific scientific capabilities on a project-by-project basis.

What sets them apart

As one of the world's leading biomedical research universities, Rockefeller brings a caliber of fundamental science that few European partners can match in immunology and infection biology. Their value in an EU consortium is as a non-associated third-country expert — they add scientific prestige, access to US research infrastructure, and deep knowledge in host-pathogen biology. For consortium builders, including Rockefeller signals scientific ambition and strengthens applications in competitive health calls.

Highlights from their portfolio

• HIVACAR
  Their only funded H2020 project (EUR 706,250), addressing HIV functional cure through combination immunotherapies and personalised vaccines — a high-impact translational health challenge.
• HGB-StIC
  Their most recent project, investigating why some children are genetically predisposed to severe Staphylococcal infections — a question at the frontier of human genetics and pediatric infectious disease.
• QuantPalm_immunity
  Connects protein biochemistry (palmitoylation) directly to immune defense against intracellular pathogens, bridging fundamental chemistry with infection biology.